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Background. Allergic rhinitis is a disease with polarization towards Th
2
and a defect of regulatory T cells. Immunological changes
have been reported after immunotherapy treatment. However, there is not much known about the natural course of allergic rhinitis
with respect to clinical manifestation and the relation with immunological responses. Objective. To evaluate clinical symptoms of
allergic rhinitis, in relation to in vivo allergen-specific skin responses and in vitro allergen-specific effector and regulatory T cells
determined at baseline and after two years.Methods. From a large trial, 59 children were randomly selected.The following variables
were compared: clinical symptoms, allergen skin tests, specific IgE, T-cell proliferation, IL-5, IL-13, IFN-gamma, IL-10, TGF-beta,
CD4+CD25hi cells, and Foxp3 expression. Results. Allergic symptoms had decreased after two years. Whereas skin test reactions
correlated between years 0 and 2, there was no change in the size of the reaction. Also, proinflammatory reactions did not change
after two years, with a positive correlation between years 0 and 2. No relevant changes were observed with respect to regulatory
cells. Conclusion. Whereas, comparable to immunotherapy, allergic complaints decrease, the immunological changes of specific
T-cell activity (both effector cells and regulator cells) which are observed after immunotherapy, do not change.
1. Introduction
Allergic rhinitis (AR) is a common chronic illness affecting
10% to 20% of the children worldwide [1], and its prevalence
has significantly increased among children over the last two
decades. AR is clinically defined as a symptomatic disorder
of the nose induced by an IgE-mediated inflammation after
exposure to an allergen. In the immediate response to an
antigen (the early-phase allergic reaction), histamine and
other inflammatory mediators are released from mast cells
in the nasal mucosa [2]. This causes the characteristic nasal
symptoms which include sneezing, itching, rhinorrhoea,
and nasal congestion. A late-phase allergic reaction occurs
approximately 4 to 12 hours after antigen exposure, with nasal
congestion as the predominant symptom. During this phase,
inflammatory cells such as eosinophils and T cells infiltrate
the mucosa. The Th
2
-polarized immune response especially,
with secretion of cytokines such as IL-4, IL-5 and IL-13 and a
defect of Th1 cells producing IFN-gamma, play a central role
in the late phase allergic response [2–4].
It has been observed that the immune response to aller-
gens is the result of a fine balance between allergen-specific
Th
2
cells and T regulatory cells (Tregs) [5]. Tregs include
a broad spectrum of CD4+ T-cell subpopulations such as
natural thymic-derived Treg cells (nTreg) characterized by
their CD4+CD25+ phenotype expressing high levels of Foxp3
[6] and inducible Tr
1
cells (iTreg) which suppress immune
function by the secretion of IL10 and TGF-beta [7–9].
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From the recent literature it becomes clear that it may
be possible to interfere with the natural course of AR
by specific immunotherapy (SIT) [9–13]. SIT may induce
changes that skew Th
2
- to Th
1
-type responses [14] and by
means of tolerance induction. One of the key mechanisms
behind this tolerance induction includes induction of Treg-
type cytokines (IL-10 and TGF-beta) [9, 10] and increased
frequencies of CD4+CD25+ cells [11].
There is an unexplained variability in the clinical course
of allergic rhinitis—with persistence in some individuals and
either progression or remission in others. There is a lack of
longitudinal investigations examining the natural history of
AR. In the present study, we investigate the natural course
of AR regarding clinical manifestations of the disorder and
immunological responses in a followup of 2 years in children
with house dust mite allergy. We evaluate clinical symptoms,
in vivo skin responses due to allergen and in vitro allergen-
specific effector T cells and Treg cells during the natural
course of the disease.
2. Methods
2.1. Study Design. This study is a part of the randomized
placebo-controlled trial ISRCTN91141483 which evaluates
sublingual immunotherapy with low-dose house dust mite
allergen (2.03mcg/mLor 700 BU/mLDer p1) in childrenwith
AR [15, 16]. Patients entered the study either in September–
December 2005 or in September–December 2006 for a period
of approximately two years. Written informed consent was
obtained. The study was approved by the Ethical Review
Board of ErasmusMC-UniversityMedical Center Rotterdam.
As described elsewhere, [16] neither this low-dose form
of SLIT was effective with regard to the reduction of allergy
complaints, asthma complaints, intake of rescue medication
and disease-specific quality of life, nor was there any differ-
ence in reported side effects (both local and general) between
SLIT or placebo treatment, indicating that the dosis of the
investigated product was a low to mediate reaction. Analysis
of placebo (𝑛 = 30) and verum (𝑛 = 29) groups separately in
children participating in the present study revealed neither
differences between verum and placebo regarding clinical
symptoms (𝑃 value varied between 0.06 and 0.86) nor in
vivo skin responses (𝑃 value between 0.17 and 0.80) or in
vitro measurements of pro-inflammatory markers (𝑃 value
between 0.16 and 0.85) or regulatory T cells (𝑃 value between
0.10 and 0.89).Therefore, we decided tomerge the two groups
and consider them as one group which received placebo
during two years. This merged group forms the basis for the
present study.
2.2. Patient Selection. From themain trial, fifty-nine children
were randomly selected and invited to participate in this elab-
orate study. As in the main study, children (aged 6–18 years)
with AR and established HDM allergy were selected from the
electronic medical records in general practice. The inclusion
criteria were presence of specific IgE antibodies to HDM in
serum (≥0.7 kU/L), a history of allergic rhinitis during at least
1 year and a nasal symptom score of at least 4 out of 12 (see
below). Before scoring symptoms, nasal corticosteroids were
withheld for 4 weeks before the study period. During the total
study period patients were allowed to use rescue medication
(provided by us, i.e., levocetirizine tablets, xylometazoline
nasal spray, and levocabastine eyedrops) or another allergy
or asthma medication as long as they wrote it down on their
diary cards (see below). The presence of asthma was assessed
using the International Study of Asthma and Allergies in
Childhood (ISAAC) core questionnaire [17].
2.3. Measurement of Nasal, Eye, or Asthma Symptoms. All
participants or their parents scored their nasal, eye, and
asthma (lung) symptoms on diary cards at baseline (1 month
in October or in November) and after two years (3 months in
September–December). Nasal symptoms (sneezing, itching
nose, watery running nose, and nasal blockage), eye symp-
toms (itching, tearing, and redness), and asthma symptoms
(wheeze/breathless and dry cough during night) were scored
on a 0–3 scale (0 = none, 1 = mild, 2 = moderate, and 3 =
severe). In total, a maximal daily cumulative nasal symptom
score of 12, eye symptom score of 9, and lung symptom score
of 6 could thus be obtained.
A mean symptom score was determined by calculating
the mean daily score over the entire diary period (i.e., one
month at baseline and three months after 2 years). Only
diaries with at least 50% of the filled-out pages were included
in the analyses. In case patients used additional medication
for their allergy or asthma, theywere asked to document their
use in the patient diary throughout the 2-year period.
2.4. Skin Testing. Allergy skin testing was performed at
baseline and after 2 years by intracutaneous injection of
0.02mL Dermatophagoides pteronyssinus in the forearm
(concentration 30 SQU/mL, manufactured by ALK-Abello´,
Nieuwegein, The Netherlands). We chose to perform an
intracutaneous skin test rather than the usual skin prick test
because intracutaneous injection of the allergen is the most
feasible and convenient way to induce a late-phase response
after the early-phase skin response [18]. As a positive control,
histamine (concentration of 0.01mg/mL) was injected, and
the negative control was dilution buffer. Reactions were read
after 15min (early response) and after 6 h (late response).The
area of the skin response in mm2 was measured by a specially
developed scanning programme. The early-phase response
was expressed as a histamine equivalent intra-cutaneous
index or HEIC index. The late-phase response was expressed
as the area of the skin response in mm2. Children were not
allowed to take antihistamines within 24 h before skin testing.
2.5. Detection of House Dust Mite-Specific IgE. Serum IgE
antibodies to D. pteronyssinus were determined using the
CAP-RAST system (Pharmacia, Uppsala, Sweden), according
to the manufacturers instructions.
2.6. House-Dust-Mite-Specific T-Cell Proliferation. Blood was
drawn at baseline and after 2 years before skin testing.
Peripheral blood mononuclear cells (PBMCs) were isolated
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from heparinized blood by density centrifugation on Ficoll-
Paque Plus (GE Healthcare, Uppsala, Sweden). PBMCs were
used in a lymphocyte proliferation test (LPT). Cells were
resuspended in complete medium (RPMI + HEPES + gluta-
max supplemented with gentamicin (Gibco, Gibco BRL, Life
Technologies, Rockville, MD, USA) and 5% heat-inactivated
human serum (Sanquin, Rotterdam, The Netherlands) and
stimulated by culturing in the presence or absence of 2 IR/mL
D. pteronyssinus (Stallerge`nes, France). All cell cultures were
performed in quadruplicate in a final volume of 200mL with
a cell concentration of 2 × 106 cells/mL in 96-well round-
bottomed microtitre plates. To determine HDM-specific
proliferative responses, cells were cultured for 5 days at 37∘C,
5% CO
2
, and 95% humidity. During the last 16 h, cells were
pulsed with 0.5 𝜇Ci/well 3H thymidine (Pharmacia, UK).
Radioactivity was measured with a 𝛽-plate reader, and the
proliferative capacity was assessed by the stimulation index
(SI), calculated as the ratio of mean 3H thymidine uptake
in stimulated to that in non-stimulated cultures. The SI was
considered positive when it exceeded 2.0.
2.7. House-Dust-Mite-Specific Cytokine Production by ELISA.
To determine HDM-specific cytokine production, 1mL of
PBMCs with a concentration of 2 × 106 cells/mL was cultured
in duplicate in a 24-well plate with or without 2 IR/mL D.
pteronyssinus (Stallerge`nes France). After 5 days of culture,
supernatants were harvested and stored at −20∘C until test-
ing. IL-5, IL-13, IFN-𝛾, IL10, and TGF-beta cytokine produc-
tion was measured following the manufacturer’s instructions
(eBioscience, San Diego, CA, USA or R&D Systems, Abing-
don, UK). HDM-induced cytokine production was assessed
by subtracting the cytokine concentration of nonstimulated
from that of stimulated culture supernatants.
2.8. Detection of CD4+CD25hi Cells by FACS. For pheno-
typical analysis, cells were washed with FACS buffer (0.05%
NaN
3
, 2% BSA in PBS) and stained for 30min on ice
protected from light. For the detection of CD4+CD25hi
T cells the following anti-human antibodies were used:
FITC-conjugated anti-hCD3 (UCHT1, eBioscience), PE-
conjugated anti-hCD25 (M-A251, BD) APC-conjugated anti-
hCD4 (RPA-T4, eBioscience). Aspecific binding was pre-
vented by the use of 2% Heat Inactivated (HI) human AB
serum during staining. Afterwards the cells were washed
three times with FACS buffer and measured. Data acquisi-
tion was performed by flow cytometry (FACSCalibur; BD
Biosciences) and data analysis was performed using FlowJo
software (Treestar, Coata Mesa, CA)).
2.9. Measurement of Foxp3 Levels by Means of Real-Time
Quantitative PCR. Quantitative RT-PCR for hFoxP3 was
performed on RNA isolated from HDM-stimulated PBMC’s
(as described above). Total RNA was isolated with RNeasy
Mini Kit (Qiagen) and treated with DNAseI, according to
manufacturer’s protocol. 100 ng RNA was used as a template
for cDNA synthesis, using Superscript II reverse transcriptase
(Invitrogen) and random hexamer primers. Quantitative
PCR was performed with Taqman Universal PCRMastermix
Table 1: Baseline characteristics of the study population.
𝑁 = 59
Age, years (mean, SD) 11.6 (3.0)
Gender, male (𝑛, %) 28 (47.5%)
Wheeze/dyspnea last year (𝑛, %) 37 (62.7%)
Multisensitization (𝑛, %) 49 (83.1%)
(Applied Biosystems), preformulated primers (hFoxP3 and
housekeeping gene hHPRT) and probe mixes (“Assay on
Demand”, Applied Biosystems). PCR conditions were 2min
at 50∘C, 10min at 95∘C, followed by 40 cycles of 15 s at
95∘C and 60∘C for 1min using an ABI PRISM 7300 (Applied
Biosystems). PCR amplification of the housekeeping gene
was performed during each run for each sample to allow
normalization between samples.
2.10. Statistical Analysis. Values are presented as mean (with
standard deviation, SD), median (with interquartile range,
IQR), and median estimated difference between baseline
(year 0) and year 2. Comparisons were performed by non-
parametric analysis, using Wilcoxon signed rank test for
comparisons between baseline data and data after 2 years.The
Spearman rank test (𝑅
𝑠
) was used to assess the correlations
between year 0 and year 2. A 𝑃 value of 0.05 was considered
statistically significant. All analyses were performed using
statistical software SPSS (version 18).
3. Results
The baseline characteristics of the 59 children included in
the study are described in an earlier study [19]. Of the 59
children, 42 (71.8%) completed the 2-year study period. The
most important values are summarized in Table 1. Mean
and median values (with SD or IQR) of clinical symptoms,
in vivo allergen-induced skin tests, and in vitro specific
pro-inflammatory and regulatory responses are displayed in
Table 2.
Clinical symptoms of the nose, eye and lung all decreased
significantly two years after baseline measurement. Table 3
shows a median paired estimated difference of −1.34 (𝑃 <
0.0001) for nose symptoms, −0.29 (𝑃 = 0.02) for eye
symptoms and −0.33 (𝑃 < 0.0001) for lung symptoms. There
was a significant positive correlation between values of year
0 and year 2 for all clinical symptoms (𝑅
𝑠
between 0.56 and
0.61; 𝑃 < 0.0001).
Reactions of in vivoHDMspecific skin tests (both early as
well as late skin reactions) did not significantly change when
measured two years after the baseline measurement (Table 3,
𝑃 = 0.09 or 𝑃 = 0.07, resp., Table 3). Whereas there were no
significant changes in time, skin responses showed a positive
correlation when skin responses of year 0 and year 2 were
compared (𝑅
𝑠
= 0.44; 𝑃 = 0.005 for the early skin response
or 𝑅
𝑠
= 0.5; 𝑃 = 0.001 for the late skin response).
Relevant proinflammatory variables for AR (i.e., HDM
specific IgE, T-cell proliferation, IL-5, IL-13, and IFN-gamma)
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Table 2: Mean (SD), median (IQR), and number of different variables for year 0 and year 2.
Year 0 Year 2
Mean SD Median IQR 𝑁 Mean SD Median IQR 𝑁
Clinical symptoms
Nose (score from 0–12) 3.8 2.2 3.62 3.46 59 2.3 1.95 1.84 2.06 52
Eye (score from 0–9) 1.15 1.32 0.67 1.39 59 0.65 1.1 0.21 0.79 52
Lung (score from 0–6) 0.87 1.13 0.37 1.33 59 0.36 0.9 0.028 0.15 52
HDM-specific skin test
Early skin test (HEIC) 1.72 0.61 1.69 0.76 52 1.96 0.78 1.7 0.87 42
Late skin test (mm2) 871.4 771.6 759.2 1389.8 59 1112.4 904.6 1044.5 1418.28 42
HDM-specific proinflammatory response
Specific IgE (kU/L) 43.23 34.78 38.1 62.45 59 47.58 34.81 45.6 62.3 53
Proliferation (SI) 6.84 6.18 4.78 5.52 59 5.59 6.73 3.29 5.22 41
IL-5 (pg/mL) 892.93 1963.66 329.66 793.15 59 384.4 549.35 194.82 515.00 41
IL-13 (pg/mL) 848.54 1243.31 313.05 1206.3 59 875.31 783.25 1183.44 1494.64 41
IFN-gamma (pg/mL) 97.81 123.61 55.67 139.94 59 58.39 101.85 26.93 72.73 41
HDM-specific regulatory response
CD4+CD25hi (% of CD3+) 0.44 0.26 0.39 0.32 59 0.88 0.46 0.73 0.44 41
FoxP3 (relative expression) 3.22 2.41 2.39 2.47 59 2.8 1.75 2.4 2.65 41
IL-10 (pg/mL) 81.75 157.33 21.32 95.02 59 21.81 39.0 9.24 24.7 41
TGF-beta (pg/mL) 105.13 258.26 0.00 27.27 59 221.35 383.86 58.72 305.75 41
SD: standard deviation.
IQR: Inter Quartile Range.
were comparable between year 0 and year 2 (Table 3,𝑃 > 0.05
except for IFN-gamma which showed a significant decrease).
Whereas values did not significantly increase or decrease,
there was a significant correlation between data from year 0
and year 2 for all these markers (𝑅
𝑠
between 0.35 and 0.86),
except for IL-5 (𝑅
𝑠
= 0.27).
The frequency of regulatory CD4+CD25hi cells had
increased two years after baseline measurement. However,
other markers characteristic for regulatory cells (Foxp3, IL-
10, TGF-beta) did not increase in time (in fact for IL-10 a
decrease could be detected, Table 3). Correlations between
year 0 and year 2 for these variables were nonsignificant
(except for IL-10).
Figure 1 summarizes the above-described findings with
a decrease of clinical symptoms after 2 years in combi-
nation with a positive correlation between data of year 0
and year 2 (represented by nasal symptoms in Figure 1(a)),
comparable skin-test values for year 0 and year 2, with
a positive correlation between the two years (early skin
test is presented in Figure 1(b)), no significant change in
proinflammatory reactions (in Figure 1(c) represented as
spec IgE) with a high correlation between measurements
during the two years, and an increase of CD4+CD25hi
Treg cells without a correlation between the two years of
measurement (Figure 1(d)). As can be seen in this figure,
there is no difference in any of the values between patients
receiving placebo treatment or verum-SLIT treatment (which
they received during a period of two years in the original
trial).
4. Discussion
Results of the present study show clinical symptoms rated by
allergic patients at baseline and two years later in combination
with immunological parameters measured in vivo or in vitro.
In a time period of two years, clinical symptoms of the nose,
eye, and lung significantly decrease in children with house-
dust-mite-induced AR. Although children rate their allergy
complaints as being less than at the beginning of the study,
this decrease is not reflected in a decrease of one of the
immunological parameters.
A possible explanation for the reduction of symptoms
is that allergic rhinitis decreases in time. Whereas there
are many studies determining symptoms during followup of
SLIT treatment, there is little information on the possibility
of spontaneous remission of allergic rhinitis [12, 20]. Some
studies have reported the relationship between age and
improvement or decline of rhinitis over the years [21–23].
During an 8-year follow-up of patients with allergic rhinitis,
Nihle´n et al. [21] found a 20% remission rate, which was
higher in older patients. Broder et al. [22] described that
remission with allergic rhinitis was more likely when the
duration of the disease was shorter than 5 years.
Another plausible explanation for the reduction of symp-
toms might be that, due to participation in a study, patients
are more aware of their allergy and take more care of
their complaints, which may result in a reduction of their
symptoms. In this study, patients took (placebo) medication
during a period of two years. The effect of placebo treatment
is substantial in patients participating in a study evaluating
SLIT.
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Table 3: Paired estimated difference between year 2, and 0 (median, CIs and 𝑃-value) and Spearman correlation.
Paired estimated difference Correlation
Median 95% CI∗ Sign.# 𝑅
𝑠
† Sign.
Clinical symptoms
Nose (score from 0–12) −1.34 −1.86 −0.85 <0.0001 0.56 <0.0001
Eye (score from 0–9) −0.29 −0.62 −0.05 0.02 0.56 <0.0001
Lung (score from 0–6) −0.33 −0.58 −0.13 <0.0001 0.61 <0.0001
HDM-specific skin test
Early skin test (HEIC) 0.16 −0.03 0.35 0.09 0.44 0.005
Late skin test (mm2) 199.85 −12.55 458.2 0.07 0.5 0.001
HDM-specific pro-inflammatory response
Specific IgE (kU/L) 1.95 −0.79 6.45 0.17 0.86 <0.0001
Proliferation (SI) −0.67 −2.02 0.89 0.39 0.38 0.015
IL-5 (pg/mL) −132.1 −450.62 69.51 0.19 0.27 0.087
IL-13 (pg/mL) 133.92 −210.18 538.48 0.46 0.36 0.022
IFN-gamma (pg/mL) −44.84 −82.33 −4.00 0.01 0.35 0.027
HDM-specific regulatory response
CD4+CD25hi (% of CD3+) 0.44 0.3 0.56 <0.0001 0.18 0.27
FoxP3 (relative expression) −0.12 −0.67 0.41 0.64 0.24 0.13
IL-10 (pg/mL) −39.34 −67.66 −10.56 0.002 0.357 0.024
TGF-beta (pg/mL) 41.43 0.00 144.01 0.18 0.032 0.84
∗CI: confidence interval Hodges Lehman.
#
𝑃-value, Wilcoxon.
𝑅𝑠
†: Spearman rank correlation between year 0 and year 2.
Whereas from this study it becomes clear that complaints
of patients with AR decrease over time, it is demonstrated in a
birth cohort study that the prevalence of patients developing
AR increases over the time [24]. Therefore, when children
get older the change of developing AR is increasing, but for
the patients with complaints of AR the change of having
comparable complaints two years later is decreasing.
Skin responses (measured directly after intradermal aller-
gen injection and a late response with induction of inflam-
matory cells) remain constant over time. Whereas these
responses are comparable at baseline and after two years,
these data show a positive correlation, which means that
values which are high at baseline are also high after two
years, and low values remain low during the two years. It
therefore appears that sensitization persists even in the cases
with remission of symptoms. This is underlined by a study
of Bodtger and Linneberg [25] who describe that in adult
patientswith house dustmite allergy, only 5.5%of the patients
show a remission of specific IgE after eight years, whereas
remission of symptoms occurred in 32.4% of the patients.
Also, a recent study of Kong et al. [26] describes that five years
after skin testing 96% remain skin test positive.
AR is characterized by high levels of allergen-specific
IgE and secretion of the Th
2
cytokines IL-4, IL-5 and IL-
13 [3, 27, 28]. In this study, we do not see a decrease of
these inflammatory markers two years after the baseline
measurement, whereas patients rate their symptoms as better
than before. In contrast to our findings, in patientswhodonot
receive immunotherapy, allergen-specific T-cell responses
can be reduced by means of specific immunotherapy (SIT).
The literature shows that SIT is able to reduce allergic
complaints in combination with a reduction of allergen-
induced T-cell proliferation [14] and a shift in the Th2/Th1
cytokine balance, favouring type-1 T cells [29]. This shift
could be a result of either decreased IL-4 production after
allergen stimulation [14] or enhanced IFN-𝛾 expression [30].
Some studies have found a reduction of allergen-specific IgE
in combination with an increase of specific IgG levels due
to SIT [30–32]. In the large randomized study [16], of which
this present study is a component, we determined IgG1 and
IgG4 levels in 163 children at year 0 and year 2. These results
show that IgG levels remain constant over the time with a
very high correlation between year 0 and year 2 (𝑅 is 0.74
for IgG and 0.83 for IgG4), which emphasises that the dose of
allergen administratedmight have been insufficient to induce
tolerance.
Different studies demonstrate the effect of immunother-
apy on regulatory mechanisms [9–12]. They describe a sig-
nificant increase of IL-10, and TGF-𝛽 in patients undergoing
SIT compared to untreated atopic patients (or patients receiv-
ing placebo). Moreover, the number of CD4+CD25+ cells
expressing the transcription factor Foxp3 was increased after
allergen stimulation in the immunotherapy group [13]. In
our study, results related to regulatory T cells are conflicting.
Whereas we see an increase of CD4+CD25+ cells, there is
no correlation between data of year 0 and data of year 2.
Moreover, othermarkers regarding regulation of the immune
response (i.e., Foxp3, IL-10 and TGF-beta) do not increase.
In fact, IL-10 decreases in time. From this, it is unlikely that
regulatory cells play a role in this present study; self-rated
6 Mediators of Inflammation
0
2
4
6
8
10
12
0 2 4 6 8 10 12
Nose—year 2
N
os
e—
ye
ar
 0
𝑅𝑠 = 0.56 𝑃 < 0.0001
(a)
4
3
2
1
0
43210
𝑅𝑠 = 0.44 𝑃 = 0.005
Early skin test—year 2
Ea
rly
 sk
in
 te
st—
ye
ar
 0
(b)
0
20
40
60
80
100
0 20 40 60 80 100
Specific IgE—year 2
Sp
ec
ifi
c I
gE
—
ye
ar
 0
𝑅𝑠 = 0.86 𝑃 < 0.0001
(c)
0.5
1
0
1.5
2
0.5 10 1.5 2
CD4+CD25hi —year 2
CD
4+
CD
25
hi
—
ye
ar
 0
𝑅𝑠 = 0.18 𝑃 = 0.27
(d)
Figure 1: Correlation between clinical and immunological values determined at baseline and two years later. (a) patient rated nose symptoms
(𝑛 = 52), (b) response of early skin test (𝑛 = 42), (c) specific IgE (𝑛 = 53), and (d) regulatory CD4+CD25hi T cells (𝑛 = 41). Open bullets:
verum SLIT-treatment during two years, closed bullets: placebo treatment during two years (see Section 2), dashed lines: median values, and
𝑅
𝑠
: Spearman Rank test.
allergy symptoms do decrease, but this is not the result of
an increase of regulatory cells. However, we have to keep in
mind that the number of patients used to answer this question
is small, and we should be conservative with respect to this
statement.
A limitation of the present study is that only 42 out of 59
children (71%) wanted to participate two years later. Some of
these childrenwere lost to followup (a total of seven children),
and others still participated in the main SLIT study but did
notwant to do additional skin testing or venapuncture (a total
of ten children). However, the total number of 42 children is
still an acceptable number to study possible immunological
mechanisms in relation to symptoms in a period of two years.
From this study, it can be concluded that whereas, compa-
rable to SIT, allergic complaints decrease, the immunological
changes of HDM-specific T-cell activity (both effector cells
and regulator cells) which are observed after immunotherapy
do not change. This decrease in clinical symptoms might be
explained by the placebo effect, since patients participated
in a study and took (placebo) medication during a period
of two years. It may be concluded that SIT plays an active
role in tolerance induction in the patients immune system;
whereas during the two years of this study, allergic complaints
reduce without any difference in immunological parameters
as determined in this study.
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